Clinical Trials
159 trialsSelinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms
Zhongshan Hospital (Xiamen), Fudan University
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
PREeMPT
Medical College of Wisconsin
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Duke University
MYELO-CAN:TXA
University of Manitoba
MYELO-CAN:ABX
University of Manitoba
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
University Health Network, Toronto
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Weill Medical College of Cornell University
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Memorial Sloan Kettering Cancer Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Istituto Clinico Humanitas
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
PTBCy
St. Petersburg State Pavlov Medical University
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
SoraGVL
St. Petersburg State Pavlov Medical University
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
AIRPORT-MPN
Ottawa Hospital Research Institute
FluBuBe
St. Petersburg State Pavlov Medical University
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center